Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palifermin for Oral Mucositis in Head and Neck Cancer
NCT00360971Phase 3Terminated
- Sponsor
- NRG Oncology
- Start
- Jul 2006
- Primary completion
- May 2008
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in oral mucositis (OM) comparing Palifermin with Placebo (2 arms). Primary endpoint: Duration of Oral Mucositis at 15 weeks. Started Jul 2006; status: terminated.
02
Drugs
palifermin
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT00360971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00360971.